Journal pre-proof study of more than 38,000 patients found timely antibiotics and indicated fluid resuscitation were associated with increased odds of returning home
In a phase II trial (TRANSCEND FL) reported in The Lancet, Palomba et al found that lisocabtagene maraleucel was active in patients with relapsed or refractory marginal zone lymphoma (MZL).
The ASCO Post
Daily News
Stay up to date with the latest clinical headlines and other information tailored to your specialty.
Thank you for signing up for the Daily News alerts. You will begin receiving them shortly.